2013 National News Releases

Webcast ImageWebcast - Live
AtriCure, Inc. at Needham & Company’s 16th Annual Healthcare Conference
04/04/17 at 10:00 a.m. ET
AtriCure, Inc. at Needham & Company’s 16th Annual Healthcare Conference
Tuesday, April 4, 2017 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Q4 and Full Year 2016 AtriCure, Inc. Earnings Conference Call
02/28/17 at 4:30 p.m. ET
Q4 and Full Year 2016 AtriCure, Inc. Earnings Conference Call
Tuesday, February 28, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure, Inc. at the Leerink Partners Global Healthcare Conference
02/16/17 at 9:30 a.m. ET
AtriCure, Inc. at the Leerink Partners Global Healthcare Conference
Thursday, February 16, 2017 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure, Inc. at the 35th Annual JP Morgan Healthcare Conference
01/12/17 at 9:30 a.m. PT
AtriCure, Inc. at the 35th Annual JP Morgan Healthcare Conference
Thursday, January 12, 2017 9:30 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/21/17AtriCure Names Two New Members to its Board of Directors
MASON, Ohio--(BUSINESS WIRE)--Mar. 21, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina Groves and B. Kristine Johnson have been appointed to its Board of Directors. In addition, the company announced that Michael Hooven and Karen Robards, two existing members of the Board of Directors, will not stand for re-elect... 
Printer Friendly Version
03/10/17AtriCure to Present at the Needham & Company’s 16th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Mar. 10, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham & Company’s 16th Annual Healthcare Conference at the Westin Grand Central Hotel in New York City on Tuesday, April 4, 2017. Management is scheduled to present at 10:00 a.m. Eastern Time. A live audio webcas... 
Printer Friendly Version
03/06/17AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs
MASON, Ohio--(BUSINESS WIRE)--Mar. 6, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Vinayak (Vini) Doraiswamy, PhD as its Senior Vice President of Clinical, Regulatory, and Scientific Affairs. Most recently, Dr. Doraiswamy served as Vice President of Global Clinical Operations at St. Jude Medical. In his role... 
Printer Friendly Version
02/28/17AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results
2016 revenue of $155.1 million – up 19.5% 2016 U.S. sales of $122.4 million – up 19.7% 2016 International sales of $32.7 million – up 18.8% MASON, Ohio--(BUSINESS WIRE)--Feb. 28, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter and full year 2016 financial results. ... 
Printer Friendly Version
02/03/17AtriCure to Announce Fourth Quarter and Full Year 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Feb. 3, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2016 financial results on Tuesday, February 28, 2017. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 28, 2017 to discuss its fourth quarter and full... 
Printer Friendly Version
01/24/17AtriCure to Present at the Leerink Partners Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Jan. 24, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Leerink Partners Global Healthcare Conference at the Palace Hotel in New York City on Thursday, February 16, 2017. Management is scheduled to present at 9:30 a.m. Eastern Time. A live audio webcast of the presentat... 
Printer Friendly Version
01/09/17AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016
MASON, Ohio--(BUSINESS WIRE)--Jan. 9, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2016 and provided 2017 financial guidance. Preliminary and unaudited revenue for fourth quarter 2016 is expected to be approximately $41.2 million, reflecting growth of... 
Printer Friendly Version
12/15/16AtriCure to Present at the 35th Annual JP Morgan Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Dec. 15, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the 35th Annual JP Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Thursday, January 12, 2017. Management is scheduled to present at 9:30 a.m. Pacific Time. A live audio webcast of the p... 
Printer Friendly Version
11/11/16AtriCure Names Sven Wehrwein to its Board of Directors
MASON, Ohio--(BUSINESS WIRE)--Nov. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Sven Wehrwein has been appointed to its Board of Directors. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. He has more than 35 years of experience as an investment banker, chief financ... 
Printer Friendly Version
11/07/16AtriCure to Present at the Piper Jaffray 28th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Nov. 7, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 28th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, November 30, 2016. Management is scheduled to present at 11:30 a.m. Eastern Time. A live audio webcast... 
Printer Friendly Version
10/27/16AtriCure Reports Third Quarter 2016 Financial Results
Revenue of $38.3 million – up 22.0% U.S. sales of $30.6 million – up 24.0% International sales of $7.8 million – up 14.9% MASON, Ohio--(BUSINESS WIRE)--Oct. 27, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2016 financial results. “We are pleased to report solid t... 
Printer Friendly Version
10/24/16AtriCure Announces Upcoming Investor Conference Schedule
MASON, Ohio--(BUSINESS WIRE)--Oct. 24, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Stifel Healthcare Conference at the Lotte New York Palace Hotel in New York City on Tuesday, November 15, 2016. Management is scheduled to present at 9:30 a.m. Eastern Time. A live audio webcast of the presentation may be access... 
Printer Friendly Version
10/04/16AtriCure to Announce Third Quarter 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Oct. 4, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the third quarter of 2016 on Thursday, October 27, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, October 27, 2016 to discuss its third quarter 2016 financial results. The call may be accesse... 
Printer Friendly Version
08/18/16AtriCure to Present at the Morgan Stanley Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Aug. 18, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York City on Wednesday, September 14, 2016. Management is scheduled to present at 11:05 a.m. Eastern Time. A live audio webcast of the presentation may ... 
Printer Friendly Version
08/04/16AtriCure Reports Second Quarter 2016 Financial Results
Revenue of $39.7 million – up 21.8% as reported, 21.5% constant currency U.S. sales of $30.9 million – up 19.9% International sales of $8.8 million – up 28.7% as reported, 27.4% constant currency MASON, Ohio--(BUSINESS WIRE)--Aug. 4, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today annou... 
Printer Friendly Version
07/22/16AtriCure to Present at the Canaccord Genuity Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 22, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Canaccord Genuity Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 10, 2016. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visit... 
Printer Friendly Version
07/11/16AtriCure to Announce Second Quarter 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the second quarter of 2016 on Thursday, August 4, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 4, 2016 to discuss its second quarter 2016 financial results. A live webcast of the c... 
Printer Friendly Version
06/21/16AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
FROST will evaluate cryoablation of peripheral nerves for the temporary management of post-operative pain MASON, Ohio--(BUSINESS WIRE)--Jun. 21, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial ... 
Printer Friendly Version
05/02/16AtriCure to Present at the UBS Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--May 2, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors p... 
Printer Friendly Version
04/28/16AtriCure Reports First Quarter 2016 Financial Results
Revenue of $35.9 million – up 20.3% as reported, 20.4% constant currency U.S. sales of $28.3 million – up 23.3% International sales of $7.7 million – up 10.1% as reported, 10.9% constant currency MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced ... 
Printer Friendly Version
04/28/16AtriCure Announces $25 Million Term Loan with Silicon Valley Bank
MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit. "We ... 
Printer Friendly Version
04/26/16AtriCure Receives FDA Clearance for New AtriClip® Device
AtriClip PRO2™ LAA Exclusion System features a streamlined hoopless end effector MASON, Ohio--(BUSINESS WIRE)--Apr. 26, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system ha... 
Printer Friendly Version
04/12/16AtriCure Announces 510(k) Clearance for the cryoFORM™ Cryoablation Probe
Clearance brings an even more flexible probe to the U.S. market for use in a variety of surgical interventions to treat cardiac arrhythmias; product was launched in Europe in October 2015 MASON, Ohio--(BUSINESS WIRE)--Apr. 12, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoFORM c... 
Printer Friendly Version
04/05/16AtriCure to Announce First Quarter 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Apr. 5, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the first quarter of 2016 on Thursday, April 28, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 28, 2016 to discuss its first quarter 2016 financial results. A live webcast of the conf... 
Printer Friendly Version
02/23/16AtriCure Reports Fourth Quarter and Full Year 2015 Financial Results
2015 revenue of $129.8 million – up 20.8% as reported, 23.8% constant currency 2015 U.S. sales of $102.2 million – up 27.4% Fourth quarter 2015 revenue of $35.9 million – up 21.9% as reported, 24.0% constant currency MASON, Ohio--(BUSINESS WIRE)--Feb. 23, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, to... 
Printer Friendly Version
02/17/16AtriCure Enrolls First Patient in Randomized Multi-Center Trial Evaluating Post-Operative Afib
This study will evaluate the effects of excluding the LAA in cardiac surgery patients at high risk of developing post-operative Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 17, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, announced today that the first patient was enrolled and treated at PinnacleHealth Hospitals in Harrisburg, Pennsylvania ... 
Printer Friendly Version
02/01/16AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 23, 2016 to discuss its fourth quarter and full year 2015 financi... 
Printer Friendly Version
01/21/16AtriCure to Present at the Leerink Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 21, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 11, 2016. Management is scheduled to present at 8:05 a.m. Eastern Time. A live audio webcast of the presentation may be accesse... 
Printer Friendly Version
01/11/16AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2015 Updates 2016 Guidance
MASON, Ohio--(BUSINESS WIRE)--Jan. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced preliminary financial results for fourth quarter and full year 2015 and updated 2016 financial guidance. Preliminary and unaudited revenue for fourth quarter 2015 is expected to be approximately $35.9 million, reflecting growth of approximately 21.9% ... 
Printer Friendly Version
12/17/15AtriCure Announces the First Patient Enrolled in International Afib Study
The collaborative study is the first international prospective randomized multicenter study of its kind WEST CHESTER, Ohio--(BUSINESS WIRE)--Dec. 17, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the CEASE (Combined Endoscopic Epicardial and Percutaneous) AF clinical study. ... 
Printer Friendly Version
11/23/15AtriCure to Present at the Piper Jaffray Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 23, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Piper Jaffray Healthcare Conference at the Palace Hotel in New York City on Tuesday, December 1, 2015. Management is scheduled to present at 10:30 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by v... 
Printer Friendly Version
10/29/15AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 29, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Stifel Healthcare Conference at the Palace Hotel in New York City on Wednesday, November 18, 2015. Management is scheduled to present at 2:15 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiti... 
Printer Friendly Version
10/27/15AtriCure Reports Third Quarter 2015 Financial Results
Revenue of $31.4 million – up 17.8% as reported, 20.6% constant currency U.S. sales of $24.7 million – up 23.0% International sales of $6.7 million – up 2.1% as reported, 13.2% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 27, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today anno... 
Printer Friendly Version
10/13/15AtriCure Completes Acquisition of nContact
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 13, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has completed its previously announced acquisition of nContact, Inc., a privately held developer of innovative cardiac ablation solutions. About AtriCure AtriCure, Inc. is a medical device company providing innovative... 
Printer Friendly Version
10/08/15AtriCure to Announce Third Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 8, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the third quarter of 2015 on Tuesday, October 27, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, October 27, 2015 to discuss its third quarter 2015 financial results. A live webcast of... 
Printer Friendly Version
10/04/15AtriCure Enters Into Definitive Agreement to Acquire nContact
Announces Preliminary Results for Third Quarter 2015, Updates Outlook for 2015 and Provides 2016 Outlook Company to Host Conference Call Monday, October 5 at 8:30am ET Acquisition expands available market opportunity Complementary product lines to provide additional solutions for serious forms of Atrial Fibrillation WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 4, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leadi... 
Printer Friendly Version
09/30/15AtriCure Announces Launch of the cryoFORM™ Cryoablation Probe
Offering expands on the company’s cryoablation suite of products by introducing an even more flexible probe for use in a variety of surgical interventions to treat cardiac arrhythmias WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 30, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the launch of the cryoFORM™ cryoablation probe, which... 
Printer Friendly Version
08/21/15AtriCure to Present at the Morgan Stanley Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 21, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York City on Friday, September 18, 2015. Management is scheduled to present at 10:30 a.m. Eastern Time. A live audio webcast of the presentation may ... 
Printer Friendly Version
07/28/15AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook
Revenue of $32.6 million – up 22.9% as reported, 26.5% constant currency U.S. sales of $25.7 million – up 29.3% International sales of $6.8 million – up 3.5% as reported, 17.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 28, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage m... 
Printer Friendly Version
07/15/15AtriCure to Present at the Canaccord 35th Annual Growth Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 15, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Canaccord 35th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation may be ... 
Printer Friendly Version
07/07/15AtriCure to Announce Second Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the second quarter of 2015 on Tuesday, July 28, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2015 to discuss its second quarter 2015 financial results. ... 
Printer Friendly Version
06/02/15AtriCure to Present at the JMP Securities Life Sciences Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jun. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the JMP Securities Life Sciences Conference at the St. Regis in New York on Wednesday, June 24, 2015. Management is scheduled to present at 9:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiti... 
Printer Friendly Version
04/29/15AtriCure Reports First Quarter 2015 Financial Results and Updates 2015 Outlook
Revenue of $29.9 million – up 20.3% as reported, 24% constant currency U.S. sales of $22.9 million – up 26.3% International sales of $7.0 million – up 3.9% as reported, 17.6% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 29, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, ... 
Printer Friendly Version
04/21/15AtriClip System Surpasses 50,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 21, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 50,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, making it not only the preferred surgi... 
Printer Friendly Version
04/08/15AtriCure to Announce First Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the first quarter of 2015 on Wednesday, April 29, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, April 29, 2015 to discuss its first quarter 2015 financial resul... 
Printer Friendly Version
04/07/15AATS Graham Foundation and AtriCure Announce James L. Cox Fellowship in Atrial Fibrillation Surgery
Fellowship provides newly graduated cardiothoracic surgeons with a unique opportunity to be trained by nationally recognized experts in atrial fibrillation surgery WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, together with the American Association for Thoracic Surgery ... 
Printer Friendly Version
03/25/15AtriCure to Present at the Needham Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 25, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Needham Healthcare Conference at the Westin Grand Central Hotel in New York on Tuesday, April 14, 2015. Management is scheduled to present at 8:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by... 
Printer Friendly Version
03/18/15AtriCure Launches Solution for Treatment of Post-Thoracotomy Pain
The CryoICE® cryo ablation probe is now available for cryoanalgesia therapy WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 18, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the availability of its cryoICE cryo ablation probe (CRYO2) to provide cryoanalgesia for temporary pain m... 
Printer Friendly Version
03/05/15AtriCure Announces 2015 Analyst & Investor Meeting
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 5, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will host an analyst and institutional investor meeting on Tuesday, March 24, 2015, in New York City from 8:00 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will include remarks from the AtriCure management team highlighting the company’s strategy for execu... 
Printer Friendly Version
03/03/15AtriCure to Present at the Barclays Capital Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 3, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Barclays Capital Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, March 10, 2015. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast of the present... 
Printer Friendly Version
02/24/15First Two Patients Enrolled and Treated in AtriCure’s Landmark Afib Study
The collaborative study between cardiac surgeons and electrophysiologists to deliver innovative solutions and new treatment options for Atrial Fibrillation WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 24, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced the first two patients have been enrolled and ... 
Printer Friendly Version
02/23/15AtriCure Reports Fourth Quarter and Full Year 2014 Financial Results
2014 revenue of $107.5 million – up 31.2% 2014 U.S. sales of $80.2 million – up 28.7% 2014 International sales of $27.3 million – up 39.2%; 39.8% constant currency Fourth quarter 2014 revenue of $29.4 million – up 34.4% WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 23, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and l... 
Printer Friendly Version
02/02/15AtriCure to Announce Fourth Quarter and Full Year 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will release its financial results for the fourth quarter and full year 2014 on Monday, February 23, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Monday, February 23, 2015 to discuss its fourth quarter and full year 2014 financi... 
Printer Friendly Version
01/19/15AtriCure to Present at the Leerink Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast and replay of the presentation w... 
Printer Friendly Version
01/14/15Douglas Seith Assumes the Role of AtriCure Chief Operating Officer; Andy Wade Promoted to Senior Vice President
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 14, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that Douglas Seith will assume the role of Chief Operating Officer. Mr. Seith will now be responsible for all global commercial organizations as well as education and clinical science programs. The company also announced that Andy Wade has been promoted... 
Printer Friendly Version
01/12/15AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2014 Issues 2015 Guidance
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 12, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage Management (“LAAM”), today announced preliminary financial results for fourth quarter and full year 2014 and issued 2015 financial guidance. Preliminary and unaudited revenue for fourth quarter 2014 is expected to be approximately $29.5 million, reflecting growth ... 
Printer Friendly Version
11/03/14AtriCure Receives FDA Approval For Pivotal Study to Enroll Non-Paroxysmal Afib Patients
AtriCure will investigate a minimally invasive approach to treat patients with persistent or long-standing persistent atrial fibrillation who have failed antiarrhythmic drug therapy. WEST CHESTER, Ohio--(BUSINESS WIRE) November 3, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced it has received approval for an Investigational Device Exemption from the U.S. Food and Drug A... 
Printer Friendly Version
10/31/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Stifel Healthcare Conference 2014 at the Palace Hotel in New York City on Tuesday, November 18, 2014. Management is scheduled to present at 3:35 p.m. Eastern Time. A live audio webcast and replay of the presentation will be a... 
Printer Friendly Version
10/30/14AtriCure Reports Third Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $26.7 million – up 32.4% U.S. sales of $20.1 million – up 26.7% International sales of $6.6 million – up 53.4%; 53.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 30, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage Management (“LAAM”), today announced financial results for the third ... 
Printer Friendly Version
10/09/14AtriCure Completes Enrollment in Post Approval Study for the Synergy™ Ablation System
This is the largest study of its kind to evaluate surgical ablation for the treatment of chronic Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced enrollment in the ABLATE Post Approval Study (PAS) is complete. As of October 3, 2014, the ABLATE PAS enrolled 3... 
Printer Friendly Version
10/03/14AtriCure to Announce Third Quarter 2014 Financial Results
WEST CHESTER, Ohio, Oct. 3, 2014 (GLOBE NEWSWIRE) -- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, will release its financial results for the third quarter of 2014 on Thursday, October 30, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, October 30, 2014 to discuss its third quarter 2014 financial results. A live webcast of the conference call will be available online fro... 
Printer Friendly Version
09/18/14AtriCure Announces the Release of the AtriClip® FLEX
Increased shaft flexibility allows a surgeon more maneuverability within a patient’s unique anatomy when excluding the left atrial appendage WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 18, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and Left Atrial Appendage Management (LAAM), today announced the introduction of the AtriClip® FLEX, a new device with a more flexible... 
Printer Friendly Version
07/29/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following th... 
Printer Friendly Version
07/24/14AtriCure Reports Second Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $26.5 million – up 29.8% U.S. sales of $19.9 million – up 28.8% International sales of $6.6 million – up 32.9%; 29.1% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 24, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced financial results for the second quarter of 2014. “We are pleased with our performan... 
Printer Friendly Version
07/16/14AtriClip® System Surpasses 34,000 Units Sold
AtriClip is the most widely used device indicated for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 16, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), today announced that it has sold more than 34,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, quickly becoming the top selling device used for eliminating the left... 
Printer Friendly Version
07/03/14AtriCure to Announce Second Quarter 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 3, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the second quarter of 2014 on Thursday, July 24, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, July 24, 2014 to discuss its second quarter 2014 financial results. A live webcast of the conference call will be available online from... 
Printer Friendly Version
05/28/14AtriCure to Present at the 9th Annual JMP Securities Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--May 28, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the 9th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Tuesday, June 24, 2014. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 90 days follo... 
Printer Friendly Version
05/21/14AtriCure Announces First Patient Enrolled in Stroke Feasibility Study
First U.S. clinical study to evaluate the safety of a novel epicardial-based left atrial appendage closure device for stroke prevention in atrial fibrillation patients. WEST CHESTER, Ohio--(BUSINESS WIRE)--May 21, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leader in surgical solutions to treat atrial fibrillation (Afib), today announced the first patient enrolled in a feasibility study using the AtriClip® Left Atrial Appendage Exclusion Sy... 
Printer Friendly Version
04/24/14AtriCure Reports First Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $24.8 million – up 27.9% U.S. sales of $18.1 million – up 23.9% International sales of $6.7 million – up 39.9%; 36.4% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 24, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced financial results for the first quarter of 2014. “We are off to a strong start in 20... 
Printer Friendly Version
04/04/14AtriCure to Announce First Quarter 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 4, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the first quarter of 2014 on Thursday, April 24, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 24, 2014 to discuss its first quarter 2014 financial results. A live webcast of the conference call will be available online from... 
Printer Friendly Version
02/28/14AtriCure to Present at the Cowen and Company 34th Annual Health Care Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 28, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 5, 2014. Management is scheduled to present at 9:20 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 day... 
Printer Friendly Version
02/27/14AtriCure Reports Fourth Quarter and Full Year 2013 Financial Results
2013 revenue of $81.9 million – up 16.6% 2013 U.S. sales of $62.3 million – up 18.4% Fourth quarter revenue of $21.9 million – up 19.2% WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 27, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced fourth quarter and full year 2013 financial results. “We are pleased with our team’s performanc... 
Printer Friendly Version
02/13/14AtriCure Prices Public Offering of Common Stock
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 13, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced the pricing of its previously announced underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $19.25 per share. AtriCure is offering 3,023,025 shares and selling stockholders are offering 1,226,975 shares of common stock. In connection with the offering, Atr... 
Printer Friendly Version
02/12/14AtriCure Announces Commencement of Public Offering of Common Stock
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 12, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that AtriCure and certain selling stockholders intend to offer shares of AtriCure common stock in a public offering. AtriCure also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. AtriCure plans to use the net proceeds... 
Printer Friendly Version
02/04/14AtriCure to Announce Fourth Quarter and Full Year 2013 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 4, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the fourth quarter and full year 2013 on Thursday, February 27, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, February 27, 2014 to discuss its fourth quarter and full year 2013 financial results. A live webcast of the conference call wil... 
Printer Friendly Version
01/20/14AtriCure to Present at the Leerink Swann 2014 Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 20, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Leerink Swann 2014 Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Wednesday, February 12, 2014. Management is scheduled to present at 11:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 3... 
Printer Friendly Version
01/09/14AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2013 and Issues 2014 Guidance
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced preliminary financial results for fourth quarter and full year 2013 and issued 2014 financial guidance. Preliminary revenue for the fourth quarter of 2013 is expected to be approximately $21.9 million, reflecting growth of approximately 19% over the fourth quarter of 2012. Based on this prelimin... 
Printer Friendly Version
01/02/14AtriCure Completes Acquisition of Estech
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 2, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced the completion of the previously announced acquisition of Endoscopic Technologies, Inc. d/b/a Estech (“Estech”). Estech develops and markets a portfolio of innovative surgical ablation devices that enable physicians to perform a variety of traditional and minimally invasive procedures using Estech’s pro... 
Printer Friendly Version
12/19/13AtriCure Announces Definitive Agreement to Acquire Estech
WEST CHESTER, Ohio--(BUSINESS WIRE)--Dec. 19, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation (Afib) medical device provider, and Endoscopic Technologies, Inc. d/b/a Estech (“Estech”), today announced that they have entered into a definitive merger agreement under which AtriCure has agreed to acquire Estech for a cash-free, debt-free up-front payment of approximately 2.1 million shares or $34 million of AtriCure common stock and up to... 
Printer Friendly Version
11/19/13AtriCure Receives FDA Approval for Investigational Study to Evaluate Stroke Prevention in Atrial Fibrillation
AtriClip™ Left Atrial Appendage Exclusion System to be Evaluated as Alternative to Anti-Coagulation Therapy WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 19, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading developer of solutions to treat atrial fibrillation (Afib), today announced the Food and Drug Administration’s (FDA) approval to begin enrollment in a clinical study of AtriCure’s AtriClip® Left Atrial Appendage Exclusion System. The stud... 
Printer Friendly Version
10/31/13AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced that it will be participating in the following upcoming investor conferences: The 2013 Canaccord Genuity Medical Technology & Diagnostics Forum at the Westin Grand Central Hotel in New York on November 14, 2013. The Piper Jaffray 2013 Annual Health Care Conference ... 
Printer Friendly Version
10/29/13AtriCure Reports Third Quarter 2013 Financial Results
Revenue of $20.1 million – up 24.8%; 24.0% constant currency U.S. sales of $15.8 million – up 28.1% International sales of $4.3 million – up 14.2%; 10.8% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 29, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced financial results for the third quarter of 2013. “We are pleased wit... 
Printer Friendly Version
10/07/13AtriCure to Announce Third Quarter 2013 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 7, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation solutions partner providing innovative products, professional education and support for clinical science to reduce the economic and social burden of atrial fibrillation, will release its financial results for the third quarter of 2013 on Tuesday, October 29, 2013. AtriCure will host a conference call at 4:30 p.m. Eastern Time on ... 
Printer Friendly Version
09/19/13Health Risks of Atrial Fibrillation Raised During Awareness Month
AtriCure Seeks to Improve Lives by Encouraging Education and Treatment for People with Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 19, 2013-- September is Atrial Fibrillation (Afib) Awareness Month and AtriCure, Inc. (Nasdaq: ATRC) encourages those who are affected to participate in “ACT Against Afib,” a new campaign focused on raising awareness of the risks of Afib and the various treatment options available. AtriCure is a leading d... 
Printer Friendly Version
09/18/13AtriCure Announces Commitment to Improve Lives of 250,000 Atrial Fibrillation Patients
Investment in Clinical Studies, Education to Advance New Technology Brings Hope to Patients Suffering from Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 18, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (Afib) solutions partner, has announced a significant multi-year strategic investment in clinical trial and educational initiatives aimed at reducing the global Afib epidemic. The announcement coincides with Atrial... 
Printer Friendly Version
09/03/13AtriCure Appoints Scott Drake to Its Board of Directors
WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 3, 2013-- AtriCure, Inc. (NASDAQ: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the exclusion of the left atrial appendage, today announced that Scott Drake, Chief Executive Officer of the Spectranetics Corporation, has been elected as Director. Donald C. Harrison, MD, one of the founders of AtriCure... 
Printer Friendly Version
08/22/13AtriCure and Century Medical Expand, Secure Distribution Agreement
Introduction of new products and stronger growth are anticipated in Japanese market WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 22, 2013-- AtriCure, Inc. (Nasdaq: ATRC) and Century Medical, Inc. (CMI) of Japan announce the extension and expansion of their multi-year agreement in which CMI will distribute AtriCure’s surgical ablation technologies to hospitals in Japan. AtriCure is a medical device company and leader in cardiac surgical ablation s... 
Printer Friendly Version
08/15/13AtriCure Announces September Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 15, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the exclusion of the left atrial appendage, today announced that it will be participating in two investor conferences in September. AtriCure management is scheduled to present at the Stifel 2013 Healthcare... 
Printer Friendly Version
08/01/13AtriCure Reports Second Quarter 2013 Financial Results; Raises 2013 Revenue Outlook
Revenue of $20.4 million – up 11.8%; 11.5% constant currency U.S. sales of $15.4 million – up 15.2% International sales of $5.0 million – up 2.4%; 1.1% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the... 
Printer Friendly Version
07/10/13AtriCure to Announce Second Quarter 2013 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 10, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the exclusion of the left atrial appendage, will release its financial results for the second quarter of 2013 on Thursday, August 1, 2013. AtriCure will host a conference call at 4:30 p.m. Eastern Time on ... 
Printer Friendly Version
06/24/13AtriCure Names David Francischelli as Vice President of Research and Development
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jun. 24, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the exclusion of the left atrial appendage, today announced that David Francischelli has joined the company as Vice President of Research and Development, effective August 6, 2013. Mr. Francischelli is an ... 
Printer Friendly Version
05/02/13AtriCure Reports First Quarter 2013 Financial Results
Highlights Revenue of $19.4 million – up 11.2%; 11.1% constant currency U.S. sales of $14.6 million – up 11.0% International sales of $4.8 million – up 11.9%; 11.7% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--May. 2, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibr... 
Printer Friendly Version
04/08/13AtriCure to Announce First Quarter 2013 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2013-- AtriCure, Inc. (Nasdaq:ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, will release its financial results for the first quarter of 2013 on Thursday, May 2, 2013. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday... 
Printer Friendly Version
03/11/13AtriCure Appoints Robert S. White to its Board of Directors
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 11, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that Robert “Bob” S. White has been appointed to the Company’s Board of Directors, effective immediately. Mr. White is a veteran in the medical technology industr... 
Printer Friendly Version
02/28/13AtriCure Reports Fourth Quarter and Full Year 2012 Financial Results
Highlights 2012 revenue of $70.2 million – up 9.1% 2012 international sales of $17.6 million – up 14.0% 4th quarter revenue of $18.4 million – up 9.5% WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 28, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or AF... 
Printer Friendly Version
02/18/13AtriCure to Announce Fourth Quarter and Full Year 2012 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 18, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the fourth quarter and full year 2012 on Thursday, February 28, 2013. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, February 28, 2013 to discuss its fourth qu... 
Printer Friendly Version
01/31/13AtriCure to Present at the Leerink Swann 2013 Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 31, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that it will present at the Leerink Swann 2013 Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 14, 2013. Management is schedul... 
Printer Friendly Version
01/16/13AtriCure Prices Public Offering of Common Stock
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 16, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced the pricing of its previously announced underwritten public offering of 3,475,000 shares of its common stock at a public offering price of $7.25 per share. In connection ... 
Printer Friendly Version
01/15/13AtriCure Announces Commencement of Public Offering of Common Stock
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 15, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole manager for the offering. AtriCure ... 
Printer Friendly Version
01/14/13AtriCure Announces Leadership Promotions
Focus is on Driving Commercial and Market Development Initiatives WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 14, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced three promotions of personnel into key leadership positions. Douglas J.... 
Printer Friendly Version
01/07/13AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2012
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 7, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, in anticipation of investor meetings in San Francisco during the week of January 7, is announcing preliminary financial results for fourth quarter and full year 2012. Preli... 
Printer Friendly Version
11/01/12AtriCure Names Michael H. Carrel President and Chief Executive Officer
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 1, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that Michael Carrel has been appointed President and Chief Executive Officer of the Company, effective immediately. Michael H. Carrel, AtriCure, Inc. Presid... 
Printer Friendly Version
11/01/12AtriCure Reports Third Quarter 2012 Financial Results
Highlights Revenue of $16.1 million – up 7.8% constant currency U.S. open heart revenue, including AtriClip, of $9.3 million – up 10.6% International sales of $3.8 million – up 16.7% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 1, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atri... 
Printer Friendly Version
10/18/12AtriCure to Announce Third Quarter 2012 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 18, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the third quarter of 2012 on Thursday, November 1, 2012. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 1, 2012 to discuss its third quarter 2012 fina... 
Printer Friendly Version
09/17/12First Patient Successfully Treated with Innovative Procedure Focused on Most Challenging Atrial Fibrillation Patient Segment
NORFOLK, Va.--(BUSINESS WIRE)--Sep. 17, 2012-- Sentara Heart Hospital is leading the way in an innovative Atrial Fibrillation (AF) procedure for what is typically the most difficult to treat or persistent, forms of AF. This past week, surgeons and cardiologists at Sentara Heart Hospital were the first in the world to begin performing surgeries in the Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study (Staged DEEP) fea... 
Printer Friendly Version
09/12/12AtriCure Launches Three-Year Post-Approval Study For the Surgical Correction of Atrial Fibrillation
WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 12, 2012-- AtriCure, Inc. (NASDAQ: ATRC), the leader in surgical ablation for the treatment of Atrial Fibrillation, has announced FDA approval of the ABLATE Post Approval Study (PAS). This landmark three-year, 350 patient study is a follow-up to the company’s December 14, 2011 FDA approval of the AtriCure Synergy Ablation System for the surgical treatment of Atrial Fibrillation (AF). AtriCure is the first and... 
Printer Friendly Version
08/02/12AtriCure Reports Second Quarter 2012 Financial Results
Highlights Record revenue of $18.3 million – up 10.5% constant currency U.S. open heart revenue, including AtriClip, of $10.1 million – up 13.8% Record International sales of $4.9 million – up 24.8% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 2, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems ... 
Printer Friendly Version
08/02/12AtriCure Reports Resignation of Chief Executive Officer
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 2, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that David J. Drachman, Chief Executive Officer and President of the Company, resigned from his positions with the Company. Mr. Drachman will continue to serve the Company... 
Printer Friendly Version
07/23/12AtriCure to Announce Second Quarter 2012 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 23, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the second quarter of 2012 on Thursday, August 2, 2012. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 2, 2012 to discuss its second quarter 2012 financ... 
Printer Friendly Version
06/27/12AtriCure to Present at the Seventh Annual JMP Securities Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jun. 27, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that it will present at the Seventh Annual JMP Securities Healthcare Conference at the Peninsula Hotel in New York on Friday, July 13, 2012. Management is scheduled to pr... 
Printer Friendly Version
05/02/12AtriCure Reports First Quarter 2012 Financial Results
Highlights Record revenue of $17.5 million – up 11.8% Record U.S. product sales of $13.2 million – up 8.8% Record International sales of $4.3 million – up 25.1% (constant currency) Record U.S. AtriClip sales of $1.8 million – up 18.8% WEST CHESTER, Ohio--(BUSINESS WIRE)--May. 2, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader i... 
Printer Friendly Version
04/23/12AtriCure to Announce First Quarter 2012 Financial Results
WEST CHESTER, Ohio, Apr 23, 2012 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the first quarter of 2012 on Thursday, May 3, 2012. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Thursday, May 3, 2012 to discuss its first quarter 2012 financial results. A live ... 
Printer Friendly Version
03/06/12AtriCure to Present at 24th Annual Roth Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 6, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation and systems for the exclusion of the left atrial appendage, today announced that it will participate in the 24th Annual Roth Conference at the Ritz Carlton hotel in Laguna Niguel, California. Management is scheduled to present on Monday, March 12, 2012 at... 
Printer Friendly Version
02/27/12AtriCure Reports Fourth Quarter and Full Year 2011 Financial Results
Highlights 2011 revenue of $64.4 million – up 9% 2011 international sales of $15.5 million – up 35% 4th quarter international sales of $4.4 million – up 32% FDA approves Synergy Ablation System for the treatment of atrial fibrillation Expanded credit facility – increased capacity WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 27, 2012-- ... 
Printer Friendly Version
02/21/12AtriCure to Announce Fourth Quarter and Full Year 2011 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 21, 2012-- AtriCure, Inc. (Nasdaq:ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the fourth quarter and full year 2011 on Monday, February 27, 2012. AtriCure will host a conference call at 4:30 p.m. Eastern time on Monday, February 27, 2012, to discuss its fourth quarte... 
Printer Friendly Version
02/09/12AtriCure Announces February Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 9, 2012-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it will participate in the following upcoming investor conferences: The Leerink Swann 2012 Global Healthcare Conference at the Waldorf Astoria hotel in New York. Management is scheduled to presen... 
Printer Friendly Version
12/16/11AtriCure's Synergy Ablation System Receives FDA Approval for the Treatment of Atrial Fibrillation
First and Only System in the United States Approved to Treat Patients with Persistent and Long-Standing Persistent Atrial Fibrillation WEST CHESTER, Ohio, Dec 16, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that the U.S. Food and Drug Administration (FDA) has approved AtriCure's Synergy Ablation... 
Printer Friendly Version
12/16/11AtriCure’s Synergy Ablation System Receives FDA Approval for the Treatment of Atrial Fibrillation
First and Only System in the United States Approved to Treat Patients with Persistent and Long-Standing Persistent Atrial Fibrillation WEST CHESTER, Ohio--(BUSINESS WIRE)--Dec. 16, 2011-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that the U.S. Food and Drug Administration (FDA) has approved AtriCure’s Syn... 
Printer Friendly Version
11/17/11Update on AtriCure's DEEP AF Feasibility Trial
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 17, 2011-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it has closed enrollment in its DEEP AF feasibility trial. DEEP AF was designed to evaluate the safety and efficacy of combining AtriCure’s minimally invasive products with catheter technologies to treat patients w... 
Printer Friendly Version
11/10/11AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio, Nov 10, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it will participate in the following upcoming investor conferences: The Lazard Capital Markets 8th Annual Healthcare Conference at the Pierre Hotel in New York. Management is scheduled to present on ... 
Printer Friendly Version
11/01/11AtriCure Reports Third Quarter 2011 Financial Results
Highlights Revenue of $15.2 million - 5% growth International sales of $3.5 million - up 19% U.S. sales of the AtriClip system of $1.4 million FDA Circulatory System Devices Panel recommends approval of AtriCure's Synergy Ablation System for the treatment of AF WEST CHESTER, Ohio, Nov 01, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company an... 
Printer Friendly Version
10/26/11AtriCure's Synergy Ablation System Receives a Recommendation from FDA Expert Advisors
Circulatory System Devices Panel Votes in Favor of FDA Approval for AtriCure's Surgical Ablation System to Treat Atrial Fibrillation WEST CHESTER, Ohio, Oct 26, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that AtriCure's Synergy Ablation System received a vote of approval from the Circulatory System Dev... 
Printer Friendly Version
10/20/11AtriCure to Announce Third Quarter 2011 Financial Results
WEST CHESTER, Ohio, Oct 20, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the third quarter ended September 30, 2011 on Tuesday, November 1, 2011. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Tuesday, November 1, 2011 to discuss its third quarter 2011 financi... 
Printer Friendly Version
09/19/11FDA Panel to Review AtriCure's Synergy Ablation System on October 26
WEST CHESTER, Ohio, Sep 19, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that a U.S. Food and Drug Administration's (FDA) Circulatory System Devices Panel meeting is scheduled to review AtriCure's Premarket Approval Application (PMA) for its Synergy Ablation System on October 26, 2011. AtriCure subm... 
Printer Friendly Version
08/25/11AtriCure Announces September Investor Conference Schedule
WEST CHESTER, Ohio, Aug 25, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it will participate in the following investor conferences in September: The Kaufman Brothers 14th Annual Investor Conference at the W Hotel in New York. Management is scheduled to present on September ... 
Printer Friendly Version
08/02/11AtriCure Reports Second Quarter 2011 Financial Results
Highlights Record revenue of $16.8 million - 18% growth International sales up 75% to a record $4.1 million Awarded $1.0 million grant for the development and commercialization of a minimally invasive AtriClip system Launch of cryoICE BOX during quarter Initiating 3Q launch of advanced ablation clamp, Isolator Synergy Access(R) WEST CHESTER... 
Printer Friendly Version
08/01/11AtriCure to Present at the 31st Annual Canaccord Genuity Growth Conference
WEST CHESTER, Ohio, Aug 01, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it will present at the 31st Annual Canaccord Genuity Growth Conference at the InterContinental Hotel in Boston on Wednesday, August 10, 2011. Management is scheduled to present at 11:30 a.m. Eastern Time. A live audio... 
Printer Friendly Version
07/18/11AtriCure to Announce Second Quarter 2011 Financial Results
WEST CHESTER, Ohio, Jul 18, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq:ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the second quarter ended June 30, 2011 on Tuesday, August 2, 2011. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Tuesday, August 2, 2011 to discuss its second quarter 2011 financial ... 
Printer Friendly Version
05/04/11AtriCure Reports First Quarter 2011 Financial Results
Highlights Revenue of $15.6 million - 12% growth $1.5 million in U.S. sales of the AtriClip(R) system Record revenue from international sales - $3.5 million Adjusted EBITDA of $0.3 million Expanded credit facility - increased capacity and reduced interest rates Obtained FDA clearance and initiating 2Q U.S. launch of Synergy Access(R... 
Printer Friendly Version
04/20/11AtriCure to Announce First Quarter 2011 Financial Results
WEST CHESTER, Ohio, Apr 20, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the first quarter ended March 31, 2011 on Wednesday, May 4, 2011. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Wednesday, May 4, 2011 to discuss its first quarter 2011 financial ... 
Printer Friendly Version
04/18/11AtriCure to Present at the Tenth Annual JMP Securities Research Conference
WEST CHESTER, Ohio, Apr 18, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it will present at the Tenth Annual JMP Securities Research Conference at the Ritz-Carlton San Francisco on Tuesday, May 10, 2011. Management is scheduled to present at 2:30 p.m. Pacific Time. A live audio webcast and... 
Printer Friendly Version
02/17/11AtriCure Announces March Investor Conference Schedule
WEST CHESTER, Ohio, Feb 17, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it will participate in the following investor conferences in March: The RBC Capital Markets Healthcare Conference at the Grand Hyatt Hotel in New York. Management will participate in the "Innovations in ... 
Printer Friendly Version
02/16/11AtriCure Reports Record Fourth Quarter 2010 Financial Results
Fourth Quarter Highlights Record revenue of $16.4 million - 20% constant currency growth $1.3 million in U.S. sales of the AtriClipTM system Record $1 million of positive adjusted EBITDA First positive net income quarter Filed final clinical PMA module for ABLATE in support of an AF indication WEST CHESTER, Ohio, Feb 16, 2011 (BUSINESS WIRE) ... 
Printer Friendly Version
02/08/11AtriCure to Announce Fourth Quarter 2010 Financial Results
WEST CHESTER, Ohio, Feb 08, 2011 (BUSINESS WIRE) --AtriCure, Inc. (NASDAQ:ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the fourth quarter ended December 31, 2010 on Wednesday, February 16, 2011. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Wednesday, February 16, 2011 to discuss its fourth quarter 2010 ... 
Printer Friendly Version
12/02/10First Patient Enrolled in AtriCure's DEEP AF Feasibility Trial
WEST CHESTER, Ohio, Dec 02, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, announced initial patient enrollment in its DEEP AF feasibility trial. The first procedure was performed in a new, state-of-the-art hybrid room at Sentara Norfolk General Hospital in Norfolk, Virginia by Jonathan Philpott, M.D., Director of th... 
Printer Friendly Version
11/09/10AtriCure Announces November/December Investor Conference Schedule
WEST CHESTER, Ohio, Nov 09, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it will participate in the following upcoming investor conferences: The 4th Annual Maxim Group Growth Conference at the Grand Hyatt New York. Management is scheduled to present at 8:30 a.m. Eas... 
Printer Friendly Version
11/02/10AtriCure Reports Third Quarter 2010 Financial Results
Third Quarter Highlights Revenue of $14.5 million - 10% constant currency growth Successful U.S. launch of the AtriClip(TM) system - sales of $1.0 million Gross margin of 77.2% - 190 basis point expansion Positive cash from operations of $0.3 million Continued positive progress toward ABLATE submission and an AF indication WEST CHESTER, Ohio,... 
Printer Friendly Version
10/19/10AtriCure to Announce Third Quarter 2010 Financial Results
WEST CHESTER, Ohio, Oct 19, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq:ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release its financial results for the third quarter ended September 30, 2010 on Tuesday, November 2, 2010. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Tuesday, November 2, 2010 to discuss its third quarter 2010 financia... 
Printer Friendly Version
09/08/10AtriCure Announces September Investor Conference Schedule
WEST CHESTER, Ohio, Sep 08, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it will participate in the following investor conferences during September: The UBS Global Life Sciences Conference at the Grand Hyatt New York. Management is scheduled to present at 3:00 p.m. Eastern Ti... 
Printer Friendly Version
08/04/10AtriCure Reports Record Second Quarter 2010 Financial Results
Highlights Revenue of $14.2 million - strengthening U.S. revenues of $11.8 million Positive cash from operations during the quarter of $1.1 million Loss from operations improves 58 percent - record low of $0.4 million Obtained commitment to expand borrowing capacity under existing credit facility Obtained FDA clearance and initiated launch of the AtriClipTM ... 
Printer Friendly Version
07/15/10AtriCure Announces August Investor Conference Schedule
WEST CHESTER, Ohio, Jul 15, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will participate in the following investor conferences during August: The BMO Capital Markets 10th Annual Focus on Healthcare Conference at the Sheraton New York Hotel and Towers. Management is scheduled to present at 11:15 a.m. on Thursday, August 5, 2010.... 
Printer Friendly Version
07/14/10AtriCure to Announce Second Quarter 2010 Financial Results
WEST CHESTER, Ohio, Jul 14, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the second quarter ended June 30, 2010 on Wednesday, August 4, 2010. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Wednesday, August 4, 2010 to discuss its second quarter 2010 financial results. A live web cast of the conference call will be av... 
Printer Friendly Version
06/14/10AtriCure's AtriClip(TM) System Receives FDA 510(k) Clearance
WEST CHESTER, Ohio, Jun 14, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it received clearance from the FDA for its AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion system. The AtriClip system is designed to safely and effectively exclude the left atrial appendage. Initial launch in the United States is anticipated to begin later this month w... 
Printer Friendly Version
05/25/10AtriCure Announces June Investor Conference Schedule
WEST CHESTER, Ohio, May 25, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will participate in the following investor conferences during June: The Noble Financial Sixth Annual Equity Conference at the Hard Rock Hotel in Hollywood, Florida. Management is scheduled to present at 9:30 a.m. Eastern Time on June 8, 2010. ... 
Printer Friendly Version
05/10/10AtriCure Reports First Quarter 2010 Financial Results
Highlights Revenues of $14 million; strongest performance of the past six quarters International revenues up 27% to $2.9 million DEEP AF feasibility trial approved by the FDA WEST CHESTER, Ohio, May 10, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced revenues of $14.0 million for its first qua... 
Printer Friendly Version
05/10/10AtriCure Announces Conditional Approval of DEEP AF Feasibility Trial
WEST CHESTER, Ohio, May 10, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it has received conditional approval from the FDA to evaluate the safety and efficacy of a dual epicardial/ endocardial procedure (DEEP), or hybrid procedure, to treat patients with persistent and long-standing persistent atrial fibrillation (AF). The trial will be conducted at fi... 
Printer Friendly Version
04/27/10AtriCure to Present at the Ninth Annual JMP Securities Research Conference
WEST CHESTER, Ohio, Apr 27, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will participate in the Ninth Annual JMP Securities Research Conference at The Ritz-Carlton hotel in San Francisco, California on Tuesday, May 11, 2010. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 9:00 a.m. Eastern Time. A live audio ... 
Printer Friendly Version
04/23/10AtriCure to Announce First Quarter 2010 Financial Results
WEST CHESTER, Ohio, Apr 23, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq:ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the first quarter ended March 31, 2010 on Monday, May 10, 2010. AtriCure will host a conference call at 5:00 p.m. Eastern Time on Monday, May 10, 2010 to discuss its first quarter 2010 financial results. A live web cast of the conference call will be available online ... 
Printer Friendly Version
03/03/10AtriCure to Present at 22nd Annual Roth OC Growth Stock Conference
WEST CHESTER, Ohio, Mar 03, 2010 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will participate in the Roth Capital Partners 22nd Annual OC Growth Stock Conference at the Ritz-Carlton Laguna Niguel in Dana Point, California on Monday, March 15, 2010. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 3:00 p.m. Pacific ... 
Printer Friendly Version
02/18/10AtriCure Reports Fourth Quarter and Full Year 2009 Financial Results
Highlights Fourth quarter revenues up 14.4 percent to $13.8 million 2009 record adjusted EBITDA of $1.6 million - improvement of $7.2 million 2009 cash provided by operations of $0.4 million - improvement of $6.1 million 2009 record international sales of $10.4 million - up 24.9 percent Definitive settlement agreement executed with the DOJ WEST CHESTER, Ohio, Feb 18, 2010 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation... 
Printer Friendly Version
02/05/10AtriCure to Announce Fourth Quarter and Full Year 2009 Financial Results
WEST CHESTER, Ohio, Feb 05, 2010 (BUSINESS WIRE) -- AtriCure, Inc. (NASDAQ:ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the fourth quarter and year ended December 31, 2009 on Thursday, February 18, 2010. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Thursday, February 18, 2010 to discuss its fourth quarter and full year 2009 financial results. A live web cas... 
Printer Friendly Version
02/02/10AtriCure Announces Definitive Settlement with the Department of Justice
WEST CHESTER, Ohio, Feb 02, 2010 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it has executed a definitive agreement with the Department of Justice (DOJ) and the Office of Inspector General of the Department of Health and Human Services to resolve the issues raised in the DOJ's investigation and the related qui tam complaint regarding the marketing of the ... 
Printer Friendly Version
11/23/09AtriCure to Present at Piper Jaffray Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 23, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will participate in the Piper Jaffray Healthcare Conference at the New York Palace Hotel on Tuesday, December 1, 2009. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 4:00 p.m. Eastern Time. A live audio webcast and ... 
Printer Friendly Version
11/04/09AtriCure Reports Third Quarter 2009 Financial Results
Third Quarter Highlights Non-GAAP operating loss improves 63% to a record $0.7 million Record adjusted EBITDA of $0.7 million Record non-GAAP net loss per share of $0.06 Year-to-date cash provided by operations of $0.3 million European approval and initial launch of the AtriClip™ System Settlement reserve established related to DOJ investigation WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 4, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surg... 
Printer Friendly Version
11/04/09AtriCure Announces Tentative Settlement with the Department of Justice
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 4, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it has reached a tentative agreement, subject to completion and approval of a written settlement agreement, with the Department of Justice (DOJ) to resolve the issues raised in the DOJ’s investigation and the related qui tam complaint regarding the marketing of the Co... 
Printer Friendly Version
11/02/09AtriCure to Present at Canaccord Adams Cardiovascular Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 2, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will participate in the Canaccord Adams Cardiovascular Conference at Hotel Nikko in San Francisco on Tuesday, November 10, 2009. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 3:30 p.m. Pacific Time. About AtriCure, ... 
Printer Friendly Version
10/16/09AtriCure to Announce Third Quarter 2009 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 16, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009 and management will host a conference call at 10:00 a.m. Eastern Time. A live webcast of the conference call will be available from the investor relations page of AtriCure’s ... 
Printer Friendly Version
10/06/09AtriCure Announces European Approval for its AtriClip(TM) System
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 6, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced CE Mark approval for its AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion System. The AtriClip System is designed to safely and effectively exclude the left atrial appendage and is being launched in Europe through a phased approach during the fourth quarter. ... 
Printer Friendly Version
09/18/09AtriCure Announces Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 18, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will participate in the following investor conferences during September and October: The UBS Global Life Sciences Conference at the Grand Hyatt New York Hotel on Wednesday, September 23, 2009. Management is scheduled to present at 12:30 p.... 
Printer Friendly Version
08/04/09AtriCure Reports Second Quarter 2009 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 4, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced second quarter 2009 revenues of $13.8 million and an operating loss improvement of 43.4 percent to a record $1.0 million. For the first half of 2009, adjusted EBITDA was a record $1.0 million, an improvement of $4.2 million over the first half of 2008 adjusted EBITDA loss of $3.... 
Printer Friendly Version
07/28/09AtriCure Announces August Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 28, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will participate in the following investor conferences during August: The BMO Capital Markets Focus on Healthcare Conference at the Millennium Broadway Hotel in New York on Wednesday, August 5, 2009. David J. Drachman, President and Chief Executi... 
Printer Friendly Version
07/21/09AtriCure to Announce Second Quarter 2009 Financial Results
WEST CHESTER, Ohio, Jul 21, 2009 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq:ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the second quarter ended June 30, 2009 on Tuesday, August 4, 2009 and management will host a conference call at 10:00 a.m. Eastern Time. A live webcast of the conference call will be available from the investor relations page of AtriCure's corporate web site, ww... 
Printer Friendly Version
05/05/09AtriCure Reports First Quarter 2009 Financial Results and Announces New $10 Million Credit Facility
Highlights WEST CHESTER, Ohio--(BUSINESS WIRE)--May. 5, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced first quarter 2009 revenues of $13.7 million. Revenues grew 1.1% over the first quarter of 2008 and 13.3% over the fourth quarter of 2008. “We are pleased with our first quarter results and remain confident that, despite a challenging environment, AtriCure is... 
Printer Friendly Version
04/09/09AtriCure Announces Webcast and Conference Call of First Quarter 2009 Financial Results
WEST CHESTER, Ohio, Apr 09, 2009 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the first quarter ended March 31, 2009 on Tuesday, May 5, 2009 and management will host a conference call at 10:00 a.m. Eastern Time. A live webcast of the conference call will be available from the investor relations page of AtriCure's corporate web site, www.... 
Printer Friendly Version
03/27/09AtriCure's Cryoablation System, Cryo1(TM), Receives FDA 510(k) Clearance
First Human Case Successfully Performed Using AtriCure's Cryo1 System WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 27, 2009-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in surgical cardiac ablation, today announced that its new innovative disposable cryoablation system, Cryo1, received 510(k) clearance from the Food and Drug Administration, or FDA, for the cryosurgical treatment of cardiac arrhythmias. Additionally, the first patient... 
Printer Friendly Version
02/19/09AtriCure Reports Fourth Quarter and Full Year 2008 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 19, 2009-- AtriCure, Inc.: Highlights 2008 revenues of $55.3 million – up 14% over 2007 2008 minimally invasive product revenues of $19.8 million – up 38% 2008 international revenues of $8.3 million – up 27% 25 patients enrolled to-date in EXCLUDE clinical trial AtriCure, Inc. (Nasdaq: AT... 
Printer Friendly Version
02/09/09AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2008 Financial Results
WEST CHESTER, Ohio, Feb 09, 2009 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the fourth quarter and year ended December 31, 2008 on Thursday, February 19, 2009. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Thursday, February 19, 2009 to discuss its fourth quarter and full year 2008 financial results. A live web ca... 
Printer Friendly Version
11/24/08AtriCure to Present at the Piper Jaffray Health Care Conference
WEST CHESTER, Ohio, Nov 24, 2008 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that David J. Drachman, President and Chief Executive Officer, will present at the 20th Annual Piper Jaffray Health Care Conference at the New York Palace Hotel in New York City on Wednesday, December 3, 2008 at 11:30 a.m. Eastern Time. A live audio webcast and replay of the presenta... 
Printer Friendly Version
11/04/08AtriCure Reports Strong Third Quarter 2008 Financial Results
3rd Quarter Highlights Consolidated revenues of $14.8 million - 23% growth Record revenues for domestic MIS of $5.7 million - 63% growth Record international revenues of $2.4 million - 29% growth Net loss improves 32% to $1.8 million Initiated EXCLUDE clinical trial WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 4, 2008--AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, ... 
Printer Friendly Version
10/31/08AtriCure Announces Investigation by the Department of Justice
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2008--AtriCure, Inc. (Nasdaq: ATRC), received a letter on October 27, 2008 from the U.S. Department of Justice-Civil Division (the "DOJ") informing the Company that the DOJ is conducting an investigation for potential False Claims Act and common law violations relating to the Company's surgical ablation devices. Specifically, the letter states that the DOJ is investigating the Company's marketing practices utilized in connection with its s... 
Printer Friendly Version
10/06/08AtriCure Announces Web Cast and Conference Call of Third Quarter 2008 Financial Results
WEST CHESTER, Ohio, Oct. 6 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the third quarter ended September 30, 2008 on Tuesday, November 4, 2008. AtriCure will host a conference call at 10:00 a.m. Eastern Time on Tuesday, November 4, 2008 to discuss its third quarter 2008 financial results. A live web cast of the conference call will be available online fro... 
Printer Friendly Version
09/29/08AtriCure to Participate at the Third Annual JMP Securities Healthcare Focus Conference in October
WEST CHESTER, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Third Annual JMP Securities Healthcare Focus Conference at Le Parker Meridien Hotel in New York City on October 6 at 9:30 a.m. Eastern Time. A live webcast and recording of the presentation will be available for 30 days follo... 
Printer Friendly Version
08/25/08AtriCure to Participate at the Thomas Weisel Partners Healthcare Conference and the UBS Global Life Sciences Conference in September
WEST CHESTER, Ohio, Aug. 25 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will present at the following investor conferences during September: -- The Thomas Weisel Partners Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 3, 2008. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 10:55 a.m. Eastern time. ... 
Printer Friendly Version
08/05/08AtriCure Reports Record Second Quarter 2008 Financial Results
Highlights Record consolidated revenues of $14.9 million Record revenues from domestic MIS products - $5.1 million Record international revenues of $2.3 million - 49% growth Net loss improves 43% to $1.6 million Secured $10 million credit facility - expands capital resources Reported MIS procedure times of 60 minutes and hospital stays of two days or less WEST CHESTER, Ohio, Aug. ... 
Printer Friendly Version
07/31/08AtriCure to Present at the BMO Focus on Healthcare and Canaccord Adams Global Growth Conferences in August
WEST CHESTER, Ohio, July 31 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will present at the following investor conferences during August: The BMO Focus on Healthcare Conference, Wednesday, August 6, 2008 at the Millennium Broadway Hotel in New York. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 9:00 a.m. Eas... 
Printer Friendly Version
07/10/08AtriCure Announces Web Cast and Conference Call of Second Quarter 2008 Financial Results
WEST CHESTER, Ohio, July 10 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the second quarter ended June 30, 2008 on Tuesday, August 5, 2008. AtriCure will host a conference call at 10:00 a.m. ET on Tuesday, August 5, 2008 to discuss second quarter 2008 results. A live web cast of the conference call will be available online from the investor relations page ... 
Printer Friendly Version
06/20/08The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France
WEST CHESTER, Ohio, June 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that its minimally invasive platform was highlighted during Cardiostim, a world congress in cardiac electrophysiology and cardiac techniques. On June 18, Dr. Kenneth Ellenbogen, Vice Chairman of Cardiology and Director of Clinical Cardiac Electrophysiology and Pacing at the Medical Coll... 
Printer Friendly Version
06/17/08AtriCure to Participate at the Jefferies 2nd Annual Healthcare Conference
WEST CHESTER, Ohio, June 17 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Jefferies 2nd Annual Healthcare Conference in New York City on June 26 at 12:30 p.m. ET. A webcast recording of the presentation will be available for 30 days following the presentation on AtriCure's Investor Relati... 
Printer Friendly Version
05/06/08AtriCure Reports First Quarter 2008 Financial Results
Highlights Record consolidated revenues of $13.5 million - up 26% over 2007 Record revenues from minimally invasive products - $4.9 million - up 65% Record number of minimally invasive procedures performed in 92 U.S. centers Release of Coolrail(TM) linear ablation device and ORLab(TM) mapping system WEST CHESTER, Ohio, May 6 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a med... 
Printer Friendly Version
04/18/08AtriCure Announces Web Cast and Conference Call of First Quarter 2008 Financial Results
WEST CHESTER, Ohio, April 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the first quarter ended March 31, 2008 on Tuesday, May 6, 2008. AtriCure will host a conference call at 10:00 a.m. ET on Tuesday, May 6, 2008 to discuss first quarter 2008 results. A live web cast of the conference call will be available online from the investor... 
Printer Friendly Version
03/18/08AtriCure's Coolrail(TM) Linear Ablation Pen Receives FDA 510(k) Clearance
First Case Performed Using Coolrail(TM) Pen in Combination with AtriCure's ORLab(TM) System - Expands Minimally Invasive Ablation Procedure WEST CHESTER, Ohio, March 18 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and leader in cardiac surgical ablation systems, today announced that its Coolrail(TM) linear ablation pen received 510(k) clearance from the FDA for the ablation of cardiac tissue. Additionally, the first patient was successfully treated... 
Printer Friendly Version
02/29/08AtriCure to Participate at the Rodman & Renshaw Investor Conference
WEST CHESTER, Ohio, Feb 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced its participation at the upcoming Rodman & Renshaw "Straight to the Heart" conference at the Boston Harbor Hotel on Tuesday, March 4, 2008. Attendance at the conference is by invitation only. The conference format is comprised of one-on-one meetings with no large group presentations sche... 
Printer Friendly Version
02/14/08AtriCure Reports Fourth Quarter and Full Year 2007 Record Financial Results
Highlights Record 2007 revenues of $48.3 million - up 26% over 2006 Record 2007 domestic open-heart revenues of $27.3 million - up 18% Record 2007 minimally invasive product revenues of $14.4 million - up 31% Record 2007 international revenues of $6.6 million - up 58% Fourth quarter 2007 net loss narrows to record low of $1.6 million ABLATE clini... 
Printer Friendly Version
02/12/08AtriCure to Present at Roth Capital Partners 20th Annual OC Conference
WEST CHESTER, Ohio, Feb. 12 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Roth Capital Partners 20th Annual OC Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, California on Wednesday, February 20th at 2:00 p.m. PT. A live web cast and recording of the presentatio... 
Printer Friendly Version
02/11/08AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
WEST CHESTER, Ohio, Feb. 11 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, today announced that the first patient was successfully treated in AtriCure's ABLATE clinical trial. Dr. Richard Kaplon, a well-known cardiac surgeon, performed the procedure at Mercy General Hospital in Sacramento, California. The purpose of the ABLATE clinical trial is to evaluate the safety and effectiveness of AtriCur... 
Printer Friendly Version
02/07/08AtriCure Appoints Mark A. Collar to its Board of Directors
WEST CHESTER, Ohio, Feb. 7 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, announced today the appointment of Mark A. Collar to the Company's Board of Directors. Mr. Collar recently retired from a distinguished career with The Procter & Gamble Company, including recently serving as President of the Global Pharmaceuticals and Personal Health business. "We are pleased to add Mark to the Board of Dir... 
Printer Friendly Version
02/05/08AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results
WEST CHESTER, Ohio, Feb. 5 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the fourth quarter and full year ended December 31, 2007 on Thursday, February 14, 2008. AtriCure will host a conference call at 10:00 a.m. ET on Thursday, February 14, 2008 to discuss fourth quarter and full year 2007 results. A live web cast of the conference call will be available o... 
Printer Friendly Version
01/14/08Surgeons and Electrophysiologist Publish Positive Data Using AtriCure Minimally Invasive Products
WEST CHESTER, Ohio, Jan. 14 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, today announced recently published results that report on AtriCure's proprietary minimally invasive products, which physicians have adopted to treat atrial fibrillation (AF). The results were published in the Journal of Interventional Cardiac Electrophysiology by two prominent cardiac surgeons, Dr. James R. Edgerton and Dr. Mi... 
Printer Friendly Version
01/07/08Positive Results Published Using AtriCure Minimally Invasive Products
WEST CHESTER, Ohio, Jan. 7 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, today announced that results reporting on the Company's proprietary minimally invasive products, which physicians have adopted to treat atrial fibrillation (AF), were published in The Annals of Thoracic Surgery by Dr. James H. Wudel, a prominent cardiac surgeon, and colleagues from the Nebraska Heart Hospital, Lincoln, Nebraska... 
Printer Friendly Version
11/29/07AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference
WEST CHESTER, Ohio, Nov. 29 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and leader in cardiac surgical ablation systems, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the BMO Capital Markets 2007 Healthcare Conference at the Millennium Broadway Hotel in New York City on Tuesday, December 4th, at 10:00 a.m. ET. A live web cast and recording of the presentation will be available for 30 ... 
Printer Friendly Version
11/20/07AtriCure to Present at Piper Jaffray 19th Annual Health Care Conference
WEST CHESTER, Ohio, Nov. 20 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and leader in cardiac surgical ablation systems, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Piper Jaffray 19th Annual Health Care Conference at the Pierre Hotel in New York City on Tuesday, November 27th, at 3:00 p.m. ET. A live web cast and recording of the presentation will be available for 30 days follow... 
Printer Friendly Version
11/06/07AtriCure Reports Third Quarter 2007 Financial Results
Highlights Total revenues of $12.1 million - up 29% over third quarter 2006 Net loss narrows to $2.6 million - record performance Domestic open-heart revenues of $6.7 million - up 22% over third quarter 2006 Domestic minimally invasive product revenues of $3.5 million - up 28% over third quarter 2006 Record international revenues of $1.8 million - up 65% over third quarter of 2... 
Printer Friendly Version
11/01/07AtriCure Ranked 80th in Deloitte's Technology Fast 500
WEST CHESTER, Ohio, Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc. (Nasdaq: ATRC), the leader in cardiac surgical ablation systems, has been ranked 80th in North America and 1st in Ohio in Deloitte's prestigious Technology Fast 500. The Fast 500 is a ranking of the 500 fastest-growing technology, media, telecommunications and life sciences companies by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. AtriCure achieve... 
Printer Friendly Version
10/22/07AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
WEST CHESTER, Ohio, Oct. 22 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, will release its financial results for the quarter ended September 30, 2007 on Tuesday, November 6, 2007. AtriCure will host a conference call at 10:00 am ET on Tuesday, November 6, 2007 to discuss third quarter 2007 results. A live web cast of the conference call will be available online ... 
Printer Friendly Version
10/16/07Published Results Using AtriCure Minimally Invasive Products
WEST CHESTER, Ohio, Oct. 16 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and leader in cardiac surgical ablation products, today announced that results reporting on the Company's proprietary minimally invasive products, which physicians have adopted to treat atrial fibrillation (AF), were published in the Journal of Cardiovascular Electrophysiology by Dr. James H. McClelland, an electrophysiologist, and colleagues from the Oregon Heart and Vascular ... 
Printer Friendly Version
09/20/07AtriCure to Present at 2007 UBS Global Life Sciences Conference
WEST CHESTER, Ohio, Sept. 20 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the 2007 UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City on Wednesday, September 26, at 12:30 p.m. ET. A live web cast and recording of the presentation ... 
Printer Friendly Version
09/12/07AtriCure to Present at ThinkEquity Partners 5th Annual Growth Conference
WEST CHESTER, Ohio, Sept. 12 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the ThinkEquity Partners 5th Annual Growth Conference at the St. Regis Hotel in San Francisco, California on Thursday, September 20, at 8:30 a.m. PT. A live web cast and recording of ... 
Printer Friendly Version
09/10/07AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
WEST CHESTER, Ohio, Sept. 10 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that its Cosgrove-Gillinov Left Atrial Appendage Occlusion System was successfully implanted during an open-heart surgical procedure performed by Professor Michele Genoni and Dr. Sacha Salzberg of The University of Zurich in Switzerland with the support of Dr. Marc Gillinov of... 
Printer Friendly Version
08/31/07AtriCure to Present at Roth Capital Partners 2007 New York Conference
WEST CHESTER, Ohio, Aug. 31 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Roth Capital Partners 2007 New York Conference at The Westin New York at Times Square on Thursday, September 6th, at 10:00 a.m. ET. About AtriCure, Inc. AtriCure, Inc. is a me... 
Printer Friendly Version
08/30/07AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
WEST CHESTER, Ohio, Aug 30, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Thomas Weisel Partners 2007 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 5th, at 9:45 a.m. ET. A live Web cast and recordi... 
Printer Friendly Version
08/09/07AtriCure Reports Record Second Quarter 2007 Financial Results
Highlights - Total revenues increased to $12.4 million - up 28% over second quarter 2006 - Record domestic MIS revenues of $4.0 million - up 47% over second quarter 2006 - Record 83 medical centers perform MIS procedures during the quarter - Domestic open-heart revenues of $6.8 million - up 21% over second quarter 2006 - Frigitronics(R) cardiac product line acquired - expands technology platform - Isolator(R) bipolar ablation clamp system receives 510(k) clearance for cardiac use WEST CHESTER... 
Printer Friendly Version
07/24/07AtriCure Announces Web Cast and Conference Call of Second Quarter 2007 Financial Results
WEST CHESTER, Ohio, July 24 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, will release its financial results for the quarter ended June 30, 2007 on Thursday, August 9, 2007. AtriCure will host a conference call at 10:00 am EDT on Thursday, August 9, 2007 to discuss second quarter 2007 results. A live Web cast of the conference call will be available online from ... 
Printer Friendly Version
07/09/07AtriCure's Isolator(R) Bipolar Ablation Clamp System Receives FDA 510(k) Clearance for Cardiac Use
WEST CHESTER, Ohio, July 9 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that its Isolator(R) bipolar ablation clamp system has received 510(k) clearance from the Food and Drug Administration (FDA) for the ablation of cardiac tissue. AtriCure believes that theirs is the only bipolar radiofrequency clamp system that has been cleared by the FDA for the... 
Printer Friendly Version
07/03/07AtriCure to Present at C. E. Unterberg, Towbin Emerging Growth Opportunities Conference
WEST CHESTER, Ohio, July 3 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the C. E. Unterberg, Towbin Emerging Growth Opportunities Conference at the Mandarin Oriental Hotel in New York on Wednesday, July 11th, at 2:30 p.m. ET. About AtriCure, Inc. AtriCure, Inc... 
Printer Friendly Version
06/05/07AtriCure to Present at Leerink Swann & Company Rhythm Revival: Atrial Fibrillation Roundtable Conference
WEST CHESTER, Ohio, June 5 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to participate in the Leerink Swann & Company Rhythm Revival: Atrial Fibrillation Roundtable Conference at the Grand Hyatt New York on Wednesday, June 6th. At 2:15 p.m. ET, Mr. Drachman will participate in a pan... 
Printer Friendly Version
05/24/07AtriCure Announces $16.5 Million Private Placement
WEST CHESTER, Ohio, May 24 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, today announced that it has entered into definitive agreements with certain institutional investors to raise $16.5 million from the private placement of 1,789,649 shares of its common stock. Of the total private placement, 1,683,060 shares were sold at $9.15 per share, and 106,589 shares were sold to a... 
Printer Friendly Version
05/10/07AtriCure Reports First Quarter 2007 Financial Results
Highlights - Record consolidated revenues of $10.8 million - Record domestic open revenues of $6.6 million - Full commercial release of our open Isolator Synergy(TM) ablation system - Achievement of key regulatory milestones WEST CHESTER, Ohio, May 10 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative... 
Printer Friendly Version
04/24/07AtriCure Announces Web Cast and Conference Call of First Quarter 2007 Financial Results
WEST CHESTER, Ohio, April 24 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter ended March 31, 2007 on Thursday, May 10, 2007. AtriCure will also host a Web cast and conference call at 11:00 am EDT on May 10, 2007 to discuss first quarter 2007 results. A live Web cast of the conference call will be available online from th... 
Printer Friendly Version
03/14/07AtriCure to Present at Cowen and Company 27th Annual Health Care Conference
WEST CHESTER, Ohio, March 14 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Cowen and Company 27th Annual Health Care Conference at the Marriott Copley Place Hotel in Boston, MA on Thursday, March 15th, at 8:45 a.m. ET. A live Web cast and recording of the presen... 
Printer Friendly Version
02/15/07AtriCure Reports Fourth Quarter and Full Year 2006 Financial Results
Fourth Quarter 2006 Financial Highlights * Record quarter, consolidated revenue of $10.6 million, previous high $9.6 million * Record quarter, domestic open revenue of $6.3 million, previous high $5.6 million * Record quarter, domestic MIS revenue of $3.3 million, previous high $2.8 million Full Year 2006 Financial Highlights * Consolidated revenue of $38.2 million, 24% growth * Domestic MIS revenue of $11.0 million, 66% growth... 
Printer Friendly Version
02/14/07AtriCure to Present at Roth Capital Partners 19th Annual OC Conference
WEST CHESTER, Ohio, Feb. 14 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Roth Capital 19th Annual OC Conference at the Ritz Carlton in Laguna Niguel, CA on Tuesday, February 20th, at 11:00 a.m. PT. A live Web cast and recording of the presentation will be avail... 
Printer Friendly Version
02/06/07AtriCure Receives FDA 510(k) Clearance for Isolator(TM) Synergy(TM) Bipolar Ablation System and Performs First Case
Pulsing Electrode Pairs Superior Performance in Thicker Tissues More Durable Ablation Lines WEST CHESTER, Ohio, Feb. 6 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that it has received Food and Drug Administration 510(k) clearance for its Isolator(TM) Synergy(TM) Bipolar Ablation... 
Printer Friendly Version
01/31/07AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2006 Financial Results
WEST CHESTER, Ohio, Jan. 31 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter and year ended December 31, 2006 on Thursday, February 15, 2007 after the close of the U.S. financial markets. AtriCure will also host a Web cast and conference call at 5:00 pm ET on February 15, 2007 to discuss fourth quarter and full year 2006 r... 
Printer Friendly Version
01/09/07AtriCure Hires Julie Piton as Chief Financial Officer
WEST CHESTER, Ohio, Jan. 9 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that it has hired Julie Piton, CPA, MBA as Vice President of Finance and Administration and Chief Financial Officer. Ms. Piton will commence employment at AtriCure on January 23, 2007. Prior to joining AtriCure, Ms. Piton was the Vice President of Finance and Investor Relations at ... 
Printer Friendly Version
12/14/06AtriCure Responds to Securities Class Action Lawsuit
WEST CHESTER, Ohio, Dec. 14 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that it and certain of its officers have been named as defendants in purported securities class action lawsuits filed in the United States District Court for the Southern District of New York. The suits allege violations of the federal securities laws and seek damages on behalf of pur... 
Printer Friendly Version
12/04/06AtriCure to Present at BMO Capital Markets Focus on Healthcare Conference
WEST CHESTER, Ohio, Dec. 4 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that David Jay Drachman, President and Chief Executive Officer, is scheduled to present at the BMO Capital Markets Focus on Healthcare Conference at the Mandarin Oriental in New York City on Thursday, December 7th, at 8:45 a.m. ET. A live Web cast and recording of the presentation w... 
Printer Friendly Version
11/28/06AtriCure Director Gene McGrevin Resigns to Devote Himself to New Position
WEST CHESTER, Ohio, Nov 28, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today the resignation of Gene R. McGrevin from the Company's Board of Directors, effective December 1, 2006. Mr. McGrevin has recently been appointed Chairman of the Board at a privately held medical device company that plans to file for an initial public offering o... 
Printer Friendly Version
11/22/06AtriCure to Present at 18th Annual Piper Jaffray Healthcare Conference
WEST CHESTER, Ohio, Nov. 22 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that David Jay Drachman, President and Chief Executive Officer, is scheduled to present at the 18th Annual Piper Jaffray Healthcare Conference at the Pierre Hotel in New York City on Wednesday, November 29th, at 12:30 p.m. ET. A live Web cast and recording of the presentation will ... 
Printer Friendly Version
11/08/06AtriCure Reports Third Quarter 2006 Financial Results
Third Quarter Highlights Revenue of $9.4 million, 31% year-over-year increase, exceeds high end of guidance Domestic MIS sales reach a record level of $2.8 million, with year-over-year growth of 95% International sales increased 76% year-over-year Lowered full year 2006 loss per share guidance Received European approval to market the Isolator(TM) bipolar ablation system for the treatment of cardiac arrhythmias, including ... 
Printer Friendly Version
10/27/06AtriCure to Present at C.E. Unterberg, Towbin Life Sciences Conference
WEST CHESTER, Ohio, Oct. 27 /PRNewswire-FirstCall/-- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that management is scheduled to present at the C.E. Unterberg, Towbin Life Sciences Conference at the Palace Hotel in New York on Monday, October 30, at 1:30 p.m. ET. A live Web cast and recording of the presentation will be available on the Investor Relations page of AtriCure's Web... 
Printer Friendly Version
10/19/06AtriCure Announces Web Cast and Conference Call of Third Quarter 2006 Results
WEST CHESTER, Ohio, Oct. 19 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter ended September 30, 2006 on Wednesday, November 8, 2006 after the close of the U.S. financial markets. AtriCure will also host a Web cast and conference call at 5:00 p.m. ET on Wednesday, November 8, 2006 to discuss third quarter 2006 results. A ... 
Printer Friendly Version
09/25/06AtriCure to Present at UBS Global Life Sciences Conference
WEST CHESTER, Ohio, Sept. 25 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that management is scheduled to present at the UBS Global Life Sciences Conference at Grand Hyatt New York in New York, NY on Thursday, September 28, 2006 at 8:00 a.m. ET. A live Web cast and recording of the presentation will be available on the Investor Relations page of AtriCur... 
Printer Friendly Version
09/18/06AtriCure to Present at A.G. Edwards Emerging Growth Conference 2006
WEST CHESTER, Ohio, Sept. 18 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that management is scheduled to present at the A.G. Edwards Emerging Growth Conference 2006 at The New York Palace Hotel in New York, NY on Wednesday, September 20, 2006 at 3:30 p.m. ET. A live Web cast and recording of the presentation will be available on the Investor Relations... 
Printer Friendly Version
09/10/06AtriCure Receives CE Mark Approval for Cardiac Arrhythmia Treatment With Isolator(TM) Transpolar(TM) Clamps in Europe
Products to be launched at EACTS/ESTS Joint Meeting in Stockholm WEST CHESTER, Ohio, Sept. 10 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that it has received CE Mark approval to market the Isolator Transpolar System for the treatment of cardiac arrhythmias, including atrial fibrillation (AF). The AtriCure(R) clamps are the only bipolar radiofrequen... 
Printer Friendly Version
09/07/06AtriCure to Present at Think Equity Partners 4th Annual Growth Conference
WEST CHESTER, Ohio, Sept. 7 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that management is scheduled to present at the Think Equity Partners 4th Annual Growth Conference at The Ritz-Carlton Hotel in San Francisco, CA on Monday, September 11, 2006 at 11:30 a.m. PT. A live Web cast and recording of the presentation will be available on the Investor Rela... 
Printer Friendly Version
09/06/06AtriCure to Present at Thomas Weisel Partners Healthcare Conference 2006
WEST CHESTER, Ohio, Sept. 6 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that management is scheduled to present at the Thomas Weisel Partners Healthcare Conference 2006 at The Four Seasons Hotel in Boston, MA on Thursday, September 7, 2006 at 9:45 a.m. ET. A live Web cast and recording of the presentation will be available on the Investor Relations pa... 
Printer Friendly Version
08/08/06AtriCure Reports Second Quarter 2006 Financial Results
Recent Highlights: Generated second quarter 2006 revenues of $9.6 million, up 11.7% sequentially Physicians performed MIS procedures in 65 domestic medical centers during the quarter Launched Multifunctional Isolator(TM) Transpolar(TM) Pen System Launched new Isolator(TM) Transpolar(TM) open clamp Completed treatment phase of RESTORE-SR II feasibility study WEST CHESTER, Ohio, Aug. 8 /PRNewswire-FirstCall/ -- AtriCure, Inc.... 
Printer Friendly Version
07/24/06AtriCure Announces Resignation of Chief Financial Officer - Thomas J. Etergino
WEST CHESTER, Ohio, July 24 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that Thomas J. Etergino resigned as the Company's Vice President and Chief Financial Officer. The Company expects Mr. Etergino to stay through August 18, 2006, at which point he will leave to pursue other endeavors. Until Mr. Etergino's successor is named, David J. Drachman, President... 
Printer Friendly Version
07/20/06AtriCure Announces Web Cast and Conference Call of Second Quarter 2006 Results
WEST CHESTER, Ohio, July 20 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter ended June 30, 2006 on Tuesday, August 8, 2006 after the close of the U.S. financial markets. AtriCure will also host a Web cast and conference call at 8:30 am ET on Wednesday, August 9, 2006 to discuss second quarter 2006 results. A live Web ca... 
Printer Friendly Version
07/20/06AtriCure Receives FDA 510(k) Clearance for Multifunctional Isolator(TM) Transpolar (TM) Pen System and Releases New Isolator Transpolar Open Clamp
WEST CHESTER, Ohio, July 20 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that it has received Food and Drug Administration (FDA) 510(k) clearance for its Isolator Transpolar Pen System (Pen) for pacing, sensing, stimulating, and recording during the evaluation of cardiac arrhythmias in addition to its currently FDA- cleared use for the ablation of cardiac t... 
Printer Friendly Version
05/04/06AtriCure Reports First Quarter 2006 Financial Results
- Provides 2006 Financial Guidance - WEST CHESTER, Ohio, May 4 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today financial results for the first quarter ended March 31, 2006. First quarter 2006 consolidated revenue was $8.6 million, compared to $7.5 million for the first quarter 2005 and $8.6 million for the fourth quarter 2005. First... 
Printer Friendly Version
04/25/06AtriCure Announces Web Cast and Conference Call of First Quarter 2006 Results
WEST CHESTER, Ohio, April 25 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter ended March 31, 2006 on Thursday, May 4, 2006 after the close of the U.S. financial markets. AtriCure will also host a Web cast and conference call at 5:30 pm ET on Thursday, May 4, 2006 to discuss first quarter 2006 results. A live Web cast of... 
Printer Friendly Version
04/12/06AtriCure Appoints Gene R. McGrevin to its Board of Directors
WEST CHESTER, Ohio, April 12 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today the appointment of Gene R. McGrevin to the Company's Board of Directors. Mr. McGrevin will serve on AtriCure's Compensation Committee. The appointment brings AtriCure's Board to 10 members, eight of whom are independent. Mr. McGrevin, 63, has over 30 years of senior management e... 
Printer Friendly Version
02/16/06AtriCure Reports Fourth Quarter and Full Year 2005 Financial Results
Fourth Quarter 2005 Highlights Total revenue increased 49.4% to $8.6 million Gross margin increased 230 basis points to 75.0% Performed first human cases in the U.S. using the Isolator(TM) Endoscopic Ablation System Enrolled 17 of necessary 25 patients in Restore II clinical trial Full Year 2005 Highlights Total revenue increased 61.6% to $31.0 million First full-year worldwide MIS product revenue of $6.4 million L... 
Printer Friendly Version
02/13/06AtriCure Appoints Mark R. Lanning to Its Board of Directors
WEST CHESTER, Ohio, Feb. 13 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today the appointment of Mark R. Lanning to the Company's Board of Directors. Mr. Lanning will serve on AtriCure's Audit Committee. The appointment brings AtriCure's Board to nine members, seven of whom are independent. Mr. Lanning, 51, currently serves as Vice President and Treasurer ... 
Printer Friendly Version
02/03/06AtriCure Announces Web Cast and Conference Call of Fourth Quarter 2005 Results
WEST CHESTER, Ohio, Feb. 3 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter and year ended December 31, 2005 on Thursday, February 16, 2006 after the close of the U.S. financial markets. AtriCure will also host a Web cast and conference call at 9:00 am ET on February 17, 2006 to discuss fourth quarter 2005 results. A live... 
Printer Friendly Version
11/03/05AtriCure Reports Third Quarter 2005 Financial Results
Business Highlights Generated quarterly revenue of $7.2 million, up 59.3% year-over-year Received 510(k) clearance for Isolator(TM) endoscopic ablation system First patient enrolled and treated in minimally invasive sole-therapy clinical study for the treatment of atrial fibrillation Launched Isolator(TM) bipolar pen Announced establishment of European subsidiary WEST CHESTER, Ohio, Nov. 3 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nas... 
Printer Friendly Version
10/31/05AtriCure Enrolls First Patient in Sole-Therapy Minimally Invasive Clinical Study for the Treatment of Atrial Fibrillation
WEST CHESTER, Ohio, Oct. 31 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today the enrollment and treatment of the first patient in its RESTORE-SR II clinical study for the use of the AtriCure Bipolar Ablation System in a sole-therapy, minimally invasive procedure to treat atrial fibrillation (AF). AtriCure received approval for its Investigational Device Except... 
Printer Friendly Version
10/21/05AtriCure Announces Web Cast and Conference Call of Third Quarter 2005 Results
WEST CHESTER, Ohio, Oct. 21 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter ended September 30, 2005 on Thursday, November 3, 2005 after the close of the U.S. financial markets. AtriCure will also host a Web cast and conference call at 4:30 pm ET on November 3, 2005 to discuss third quarter 2005 results. A live Web cast ... 
Printer Friendly Version
09/22/05AtriCure to Present at UBS Global Life Sciences Conference
WEST CHESTER, Ohio, Sept. 22 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that management is scheduled to present at the UBS Global Life Sciences Conference at The Grand Hyatt New York on Tuesday, September 26, 2005 at 10:00 a.m. ET. A live Web cast and recording of the presentation will be available on the Investor Relations page of AtriCure's Web site... 
Printer Friendly Version
09/09/05AtriCure Reports Second Quarter 2005 Financial Results
Business Highlights - Generated quarterly revenue of $7.7 million, up 50.9% year-over-year - Gross margins increased 140 basis points to 74.4% from 73.0% in second quarter 2004 - Completed Enable Medical Corporation acquisition for $7.0 million - Raised gross proceeds of $49.8 million in August initial public offering WEST CHESTER, Ohio, Sept 09, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing... 
Printer Friendly Version
09/02/05AtriCure Announces Web Cast and Conference Call of Second Quarter 2005 Results
WEST CHESTER, Ohio, Sept. 2 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter ended June 30, 2005 on Friday, September 9, 2005 before the opening of the U.S. financial markets. AtriCure will also host a Web cast and conference call at 9:00 am EDT on September 9, 2005 to discuss second quarter 2005 results. A live Web cast o... 
Printer Friendly Version
09/02/05AtriCure to Present at Thomas Weisel Partners Healthcare Tailwinds 2005 Conference
WEST CHESTER, Ohio, Sept. 2 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that management is scheduled to present at the Thomas Weisel Partners Healthcare Tailwinds 2005 Conference at The Four Seasons in Boston, MA on Wednesday, September 7, 2005 at 10:00 am ET. A live Web cast and recording of the presentation will be available on the Investor Relation... 
Printer Friendly Version
08/10/05AtriCure, Inc. Announces the Closing of its Initial Public Offering and the Acquisition of Enable Medical Corporation
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 10, 2005--AtriCure, Inc. (Nasdaq:ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, today announced the closing of its initial public offering and contemporaneous acquisition of Enable Medical Corporation. The company also announced that the underwriters have exercised their over-allotment option in full. AtriCure issued 4,150,000 common shares with gross proceeds of $49.8 million, ... 
Printer Friendly Version
08/04/05AtriCure, Inc. Announces Pricing of Initial Public Offering of Common Stock
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 4, 2005--AtriCure, Inc. (Nasdaq:ATRC) today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a price of $12 per share. AtriCure, Inc. has granted the underwriters a 30-day option to purchase up to an additional 150,000 shares at the initial public offering price to cover over-allotments, if any, and certain selling shareholders have also granted the underwriters an over-allotment option to purchase up to 450,000... 
Printer Friendly Version
04/20/05AtriCure, Inc. Files Registration Statement for Initial Public Offering
WEST CHESTER Ohio, April 20, 2005 -- AtriCure, Inc. announced today that it has filed a registration statement relating to the proposed initial public offering of its common stock with the U.S. Securities and Exchange Commission. UBS Investment Bank and Piper Jaffray & Co. are acting as joint book-running managers of the offering, and Thomas Weisel Partners LLC and A.G. Edwards are acting as co-managers of the offering. AtriCure, Inc. is a medical device company focused on developing... 
Printer Friendly Version